Tyemvers (botulinum toxin type A) / Chong Kun Dang, Cutia Therap - LARVOL DELTA

Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial. (PubMed, J Cosmet Dermatol) - P3 | "CKDB-501A is a safe and effective alternative to existing botulinum toxin products for treating moderate-to-severe glabellar lines, offering benefits of improved biocompatibility and reduced risk of allergic reactions."

Clinical • Journal • P3 data • Allergy • Immunology

Chong Kun Dang Bio, botulinum toxin 'TMBUS' product approval [Google translation] (HIT News) - "Chong Kun Dang Bio...announced on the 1st that it has received domestic product approval for its self-developed botulinum toxin product 'TYEMVERS Injection 100 Units (Clostridium botulinum toxin type A, hereinafter referred to as TYEMVERS Injection)' from the Ministry of Food and Drug Safety."

Korea approval • Muscle Spasticity

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type a for Injection (CU-20101) (clinicaltrials.gov) - P3 | N=554 | Active, not recruiting | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed

A Phase 3 Clinical Study to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection (CU-20101) (clinicaltrials.gov) - P3 | N=554 | Recruiting | Sponsor: Cutia Therapeutics（Wuxi）Co.,Ltd

New P3 trial

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial (clinicaltrials.gov) - P3 | N=300 | Completed | Sponsor: CKD Bio Corporation | Recruiting ➔ Completed

Trial completion

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: CKD Bio Corporation | Not yet recruiting ➔ Recruiting

Enrollment open

Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial (clinicaltrials.gov) - P3 | N=300 | Not yet recruiting | Sponsor: CKD Bio Corporation

New P3 trial

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity (clinicaltrials.gov) - P1 | N=24 | Completed | Sponsor: CKD Bio Corporation | Not yet recruiting ➔ Completed

Trial completion • Cardiovascular • Movement Disorders

Safety and Efficacy of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines (clinicaltrials.gov) - P1 | N=30 | Completed | Sponsor: CKD Bio Corporation | Recruiting ➔ Completed

Trial completion

Safety and Efficacy of CKDB-501A in Subjects With Post-stroke Upper Limb Spasticity (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: CKD Bio Corporation

New P1 trial • Cardiovascular • Movement Disorders